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Concerns have been raised that women from deprived backgrounds are less likely to be 
receiving hormone replacement therapy (HRT) treatment and its benefits, although evidence 
in support of this is lacking. 
Aim 
To investigate general practice HRT prescription trends and their association with markers of 
socioeconomic deprivation.  
Design  
Cross-sectional study of primary care prescribing data in England in 2018.  
Method 
Practice-level prescribing rate was defined as the number of items of HRT prescribed per 1000 
registered female patients over the age of 40 years. The association between Index of Multiple 
Deprivation (IMD) score and HRT prescribing rate was tested using multivariate Poisson 
regression, adjusting for practice proportions of obesity, smoking, hypertension, diabetes, 
coronary heart disease and cerebrovascular disease and practice list size.  
Results 
The overall prescribing rate of HRT was 29% lower in practices from the most deprived 
quintile compared with the most affluent (incidence rate ratio [IRR] 0.71, 95% CI 0.68-0.73). 
After adjusting for all cardiovascular disease outcomes and risk factors, the prescribing rate in 
the most deprived quintile was still 18% lower than in the least deprived quintile (adjusted IRR 
0.82, 95% CI 0.77-0.86). In more deprived practices, there was a significantly higher tendency 
to prescribe oral HRT than transdermal preparations (p < 0.001). 
Conclusion 
This study has highlighted inequalities associated with HRT prescription. This may reflect a 
large unmet need in terms of menopause care in areas of deprivation. Further research is needed 
to identify the factors from patient and GP perspectives that may explain this. 
3 
 
How this fits in 
Little is known about the relationship between hormone replacement therapy (HRT) 
prescribing rates and socioeconomic deprivation. Our analysis shows that there is an 18% 
lower HRT prescribing rate in primary care practices in the most deprived areas compared with 
the least deprived after adjusting for all cardiovascular disease outcomes and risk factors. In 
addition, women in more deprived areas who are prescribed HRT are relatively more likely to 
receive oral rather than transdermal therapy compared with women in the least deprived areas. 
More research is needed to confirm these findings, to establish the reasons for this difference 
and to identify how we can understand how inequalities in menopause support associated with 





Socioeconomic deprivation may be associated with prescribing rates in primary care. Recent 
research has looked at opiate, benzodiazepine and antibiotic prescribing, all of which have 
higher rates of prescribing in areas of greater socioeconomic deprivation1-3.   
Hormone replacement therapy (HRT) is a medication that has been subject to wide fluctuations 
in prescribing rates over recent decades. Following its introduction in the 1960s, prescribing 
rates rose and by the 1990s thirty percent of UK women aged 50-64 years were current users 
and fifty percent were ever users4.  
Evidence presented by the Women’s Health Initiative (WHI) programme (between 1996-2000) 
showed that deprivation was associated with HRT prevalence. In the least deprived areas thirty 
four percent of women were receiving HRT compared to thirty percent in the most deprived. 
However, they also found that HRT prescribing was influenced considerably more strongly by 
a woman’s medical and surgical background than by deprivation5. Other studies in the 1990s 
showed a reduced prescribing rate in lower socio economic groups6,7.  
Prescribing rates of HRT changed dramatically with the premature closure of the UK WHI 
study in 20028. The findings, which showed an increased risk of breast cancer in HRT users, 
triggered a worldwide review of practice.  The prevalence of menopause-related consultations 
fell, as did the incidence and prevalence of HRT prescribing4. Although more reassuring results 
were published they received relatively little media attention and so both women consulting 
for menopause and prescribing of HRT continued to fall9. More recent primary care prescribing 
data suggest that the prescribing of drugs in the British National Formulary section Female Sex 
Hormones and their Modulators, which includes oestrogen-containing HRT as well as 
progesterone, sildenafil and ulipristal, has gradually increased over the previous five years from 
~218,000 items in November 2014 to ~345,000 items in October 2019 (data from 
OpenPrescribing.net10) 
HRT is prescribed for the treatment of menopausal or perimenopausal symptoms such as 
vasomotor instability or vaginal atrophy. HRT can also improve a plethora of symptoms as 
captured by the Greene climacteric score11. The menopause can have a negative effect on mood 
as well as physical symptoms. Many women find that their work and home life are negatively 
affected and consult their GP during this time.  
Social deprivation is associated with a range of morbidities many of which may affect a 
clinician’s decision to prescribe HRT. Bone fractures and osteoporosis are more prevalent in 
areas of socio-economic deprivation12, and deprivation is associated with a younger age of the 
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menopause13 both of which are positive influences to prescribe. Cardiovascular disease and 
diabetes are more prevalent in more deprived areas. HRT does not increase cardiovascular risk 
when prescribed to women under 60 years of age and is cardiovascular protective (when 
prescribed as oestrogen alone). However cardiovascular risk factors and the presence of known 
cardiovascular comorbidity may dissuade a clinician from prescribing if over the age of 60 
years14. A difference in prescribing levels may also not be attributed solely to the decision-
making behaviour of the clinician but to the consulting behaviour of the woman.  
There is no recent evidence regarding whether the rates of HRT prescribing are linked to 
socioeconomic deprivation. In a climate where we are increasingly concerned about 
prescribing costs and there is still a reluctance from both women and clinicians to use HRT in 
the post-WHI era, we hypothesise that it is the women from the most deprived backgrounds 
that are least likely to receive HRT. In addition to exploring this hypothesis in relation to all 
oestrogen-containing HRT, we also look at the types of HRT prescribed (oral versus 






This is a cross-sectional study of monthly prescribing data for primary care practices in 
England in 2018, downloaded from NHS Digital (https://digital.nhs.uk)15. The dataset gives 
information for each primary care practice and their Clinical Commissioning Group, and the 
number of prescription items prescribed that month for each drug preparation. Private 
prescriptions are not recorded in these datasets. Information on GP practice list sizes (in 
January 2018), including stratification by sex and 5-year age bands, was also retrieved from 
NHS Digital16, as were British National Formulary (BNF) drug codes17.  
Data on practice-level and CCG-level socioeconomic status were obtained from Public Health 
England’s National General Practice Profiles18. Socioeconomic status was quantified using the 
Index of Multiple Deprivation (IMD) score from 2015. The IMD score combines information 
from seven domains to produce an overall relative measure of socioeconomic status (SES). The 
domains are combined using the following weights19: income deprivation (22.5%); 
employment deprivation (22.5%); education, skills and training deprivation (13.5%); health 
deprivation and disability (13.5%); crime (9.3%); barriers to housing and services (9.3%); and 
living environment deprivation (9.3%).  
 
Data Processing  
Primary care prescribing data for each month in 2018 were filtered for all oestrogen-containing 
HRT preparations and aggregated by BNF drug code to give the total number of items 
prescribed under each BNF code per practice over a year. All oral, transdermal, intranasal and 
implant preparations were included, but progesterone-only preparations – such as utrogestan 
and levonorgestrel-releasing intrauterine devices – were excluded so as not to “double count” 
HRT prescriptions (The BNF drug codes used in this analysis are given in Supplementary Table 
1.). The total number of prescribed items were then aggregated by practice, irrespective of the 
initial preparation. Practices with small numbers of patients (fewer than 500 females) or 
prescribing fewer than 50 HRT items in 2018 were then excluded, in order to help remove 
prescribing from units other than general practices (such as walk-in centres). Information on 
the following were added to the aggregated prescribing dataset: practice-level IMD score; the 
total number of females over the age of 40 years on the practice list (calculated from the 
age/sex-stratified practice list size dataset); and the practice prevalence risk factors or clinical 
conditions that may influence the prescribing of HRT (specifically, smoking, obesity, diabetes, 
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hypertension, coronary heart disease (CHD) and stroke or transient ischaemia attack (TIA)). 
Disease and risk factor prevalence estimates were taken from Quality Outcomes Framework 
returns from 2017/1820.  
Prescribing in each practice was calculated as number of HRT items per 1000 female patients 
over the age of 40 years. Practice-level prescribing was then categorised by IMD decile, 
showing the mean and 95% confidence interval (CI), where decile ten represents the practices 
with the highest IMD score (lowest socioeconomic status).  
 
Statistical Analysis  
The association between practice-level IMD score quintiles and HRT prescribing rate was 
initially testing using simple (univariate) Poisson regression. Robust standard errors were 
calculated to control for any violations in the assumption of variability equalling the mean. To 
test whether practice-level IMD was independently associated with the rate of HRT 
prescribing, multivariable stepwise Poisson regression was conducted considering factors 
which may influence decision-making when prescribing HRT, specifically: practice prevalence 
of smoking, obesity, diabetes, hypertension, CHD and stroke or TIA, as well as the practice list 
size of females over the age of 40 years. All independent variables were stratified by quintile, 
with the lowest values in magnitude assigned to quintile 1. Multicollinearity was tested using 
the variance inflation factor. The final model chosen was that most parsimonious, as judged 
using Akaike Information Criterion (AIC). In addition to exploring the association between 
deprivation and prescribing rate of all HRT items prescribed, the analysis was repeated for: 
oral preparations alone; and transdermal preparations alone, in order to ascertain whether or 
not the pattern seen across all HRT prescribing was consistent among different HRT 
preparations (implant or intranasal oestrogen was not analysed separately due to far fewer 
prescriptions). 
The results of Poisson regression analyses are presented as unadjusted or adjusted incident rate 
ratios (IRRs or aIRRs), with the lowest quintile for each variable used as the reference 
comparator. A p value < 0.05 was considered statistically significant. All data were analysed, 
and all plots generated, using the software R (v3.5.3)21. As all the data used were publicly 




Association between socioeconomic status and all hormone replacement therapy 
prescribing 
Of 7099 practices in the dataset, with 14,637,950 women over the age of 40 years, 621 (8.7%) 
practices did not meet the eligibility thresholds, thereby excluding 345,961 (2.4%) women. The 
final dataset included 6478 practices with 14,291,989 women over the age of 40 years, and 
2,677,613 prescriptions for oestrogen-containing HRT at a cost of £38,583,509. Overall, 53% 
more items of oral HRT were prescribed than transdermal HRT.  
The association between HRT prescribing rates and practice IMD score decile was examined 
(Figure 1). This shows that the prescribing rate was 39% higher in decile 1 (the decile with the 
lowest IMD scores) compared to decile 10. There was a step-wise decrease in prescribing rates 
from deciles 1 to 9 (Supplementary Table 2). 
On univariate analysis, there was a significant association between practice IMD score quintile 
and prescribing rate (IRR 0.71, 95% CI 0.68-0.73, for quintile 5 vs. quintile 1), with a 
significant reduction in prescribing rate with each quintile of practice IMD score (Table 1). 
Before running the multivariable analysis, we confirmed that there was no evidence of 
multicollinearity. The most parsimonious model on stepwise regression was found to be that 
which had all included variables. After adjusting for the practice prevalence of smoking, 
obesity, hypertension, diabetes, CHD and stroke or TIA, practice IMD score quintile remained 
an independent predictor of prescribing rates, with a 18% lower prescribing rate of HRT in the 
most deprived practices compared to the least deprived practices (aIRR 0.82, 95% CI 0.77-
0.86, quintile 5 vs. quintile 1, Table 1).  
A summary of the regression results of all variables included in the multivariable model can be 
found in Supplementary Table 3. Interestingly, of all the independent variables in the model, 
the practice prevalence of diabetes was most strongly associated with prescribing rates, with 
34% less prescribing in practices with the highest prevalence of diabetes compared to those 






Association between socioeconomic status and oral or transdermal preparation 
prescribing 
Similar relationships were found when examining only oral, or only transdermal, preparations 
alone, with both exhibiting a clear reduction in prescribing rate in practices with higher IMD 
scores on univariate analysis (oral IRR 0.83, 95% CI 0.81-0.86; transdermal IRR 0.68, 95% CI 
0.65-0.71, both for quintile 5 vs. quintile 1, Supplementary Tables 4 and 5). However, the 
difference in prescribing rates between the least and most deprived practices was more 
pronounced for transdermal preparations (45% higher in decile 1 vs. decile 10) compared to 
oral preparations (15% higher in decile 1 vs. decile 10). In the adjusted regression model, IMD 
score was an independent predictor of prescribing rates for oral preparations (aIRR 0.81, 95% 
CI 0.76-0.86, quintile 5 vs. quintile 1) but not for transdermal preparations (aIRR 0.97, 95% CI 
0.90-1.04, quintile 5 vs. quintile 1).  
The ratio of oral-to-transdermal prescribing varied by deprivation quintile, with a trend towards 
more oral prescribing in more deprived practices (oral-to-transdermal prescribing ratios by 
IMD score quintile: 1.40 (quintile [Q] 1), 1.55 (Q2), 1.67 (Q3). 1.69 (Q4), 1.62 (Q5); p < 
0.001). Specifically, practices in IMD quintiles 2 to 5 prescribed a greater proportion of oral 





This study has identified a stark association between prescribing rates for HRT at a practice 
level and socioeconomic deprivation. The overall rate of HRT prescriptions (per 1000 women 
aged 40 years and above) was 29% lower in practices from the most deprived quintile compared 
with the least deprived. After adjusting further for risk factors of cardiovascular health (obesity, 
smoking, practice prevalence of hypertension, diabetes, coronary heart disease and 
stroke/TIA), there was still an 18% lower prescribing rate in the most deprived practices 
compared with the least deprived.  
When preparation type was divided into transdermal and oral the trend remained (more 
prescribing in affluent areas); however, proportionately more oral HRT is prescribed than 
transdermal in practices with higher levels of deprivation. This trend is interesting as 
cardiovascular risk (as occurs in areas of higher deprivation) is an indicator that might lead to 
a higher ratio of transdermal HRT prescriptions (which has no increased risk of 
thromboembolism or stroke14) compared to oral HRT preparations. It may also reflect patient 
choice and a request for more oral HRT in more deprived areas. 
It appears that practices with a higher prevalence of diabetes prescribed less HRT, and it is 
possible that diabetes may influence clinical decision-making in this setting. HRT should not 
be prescribed for the prevention of diabetes; however, it has been shown to improve glycaemic 
control, particularly when prescribed as oral oestrogen22 and can be prescribed after taking 
other cardiovascular risk factors into account23. This may go some way in explaining the higher 
oral HRT prescribing in deprived areas but as we did not analyse individual patient data we 
cannot say with certainty if diabetes directly affected doctor’s decision making to either 
prescribe HRT or give an oral preparation.  




Strengths and limitations 
This work provides an analysis of prescribing of HRT in England at the practice level compared 
to the overall level of socioeconomic deprivation of individuals registered at each practice.  All 
NHS primary care prescribing is captured by NHS Digital, providing a robust and unbiased 
method for reviewing prescribing trends in England.  
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However, prescription rates and deprivation were analysed at the aggregated practice level. 
Hence, it cannot be determined from this data the extent to which there may be intra-practice 
variation in prescribing HRT associated with the socioeconomic status of the individual patient.  
Research using individual patient-level data is needed to explore this further.  Secondly, IMD 
scores represent, but are not a direct measure of, socioeconomic deprivation. Finally, the data 
we used in this analysis precluded any meaningful health economic analysis beyond perhaps 
the extra cost required to abolish the inequality in prescribing rates across deciles of 
deprivation. Further work is required to estimate the health economic benefits of appropriate 
and equitable prescribing of HRT, to include consideration of savings on diagnostic tests and 
other medications (such as antidepressants or analgesics), and of benefits to the economy and 
wider society that may be associated with HRT prescribing (such as an increased ability to 
work).  
 
Comparison existing literature 
Previous literature has shown decreased levels of prescribing HRT for women living in areas 
of more deprivation5,6. However there have not been any recent studies (post WHI publication) 
investigating the association between HRT prescription rates and socioeconomic deprivation. 
This article also looks at practice prevalence of cardiovascular risk as a possible explanation of 
decreased prescribing rates. 
 
Implication for research  
Further research is needed to explore the facilitators and barriers to prescribing HRT from a 
patient, clinician and health economic perspective, and our findings needs to be confirmed 
using individual-level primary care data. Further research also needs to be done into the HRT 
preparation types prescribed, and the reasons for prescribing more or less transdermal HRT. 
The recent HRT shortages have added a further barrier to acquiring HRT to both the patient 
and prescriber, the impact of which we are yet to establish24. 
It is likely that this analysis uncovers a larger unmet need in terms of the menopause care and 
support that is provided and utilised in areas of deprivation. The barriers to accessing support 
in and around the time of the menopause for women in areas of social deprivation needs to be 
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Figure 1. Oestrogen-containing hormone replacement therapy prescription rates 
per 1000 registered females over the age of 40, by practice Index of Multiple 
Deprivation score deciles in England (2018).  
For Index of Multiple Deprivation (IMD) deciles, decile 1 includes practices with the 
lowest IMD scores (least deprived). Bars and whiskers show the mean and 95% 







Table 1. Summary of regression analysis results for all oestrogen-containing 
hormone replacement therapy. 
Results from unadjusted and adjusted Poisson regression analyses showing the 
association between HRT prescribing rate IMD score. The multivariable model 
adjusted for the practice list size of females over the age of 40 years, and the practice 
prevalence of smoking, obesity, hypertension, diabetes, coronary heart disease and 
stroke/transient ischaemic attack. Quintile 1 – the lowest quintile – is the reference for 
all variables.  (IRR = incidence rate ratio; aIRR = adjusted incidence rate ratio; CI = 
confidence interval; HRT = hormone replacement therapy; IMD = Index of Multiple 
Deprivation) 
                    
    Unadjusted   Adjusted 
        IRR (95% CI)     aIRR (95% CI) 
Index of Multiple 
Deprivation score 
Quintile 1 Reference 1    1  
  2  0.91 (0.89 - 0.94)   0.97 (0.94 - 1.00) 
  3  0.80 (0.77 - 0.82)   0.89 (0.85 - 0.92) 
  4  0.72 (0.70 - 0.74)   0.82 (0.79 - 0.86) 





Supplementary Table 1. List of British National Formulary codes used for all oestrogen-containing 
hormone replacement therapy preparations. 
 
0604011ADAAAAAA 0604011G0BIABAU 0604011L0AAAKAK 0604011L0BTACBG 
0604011ADBBAAAA 0604011G0BJAABH 0604011L0AAARAR 0604011L0BUAABH 
0604011D0AAAAAA 0604011G0BJABBL 0604011L0AAAXAX 0604011L0BVAABI 
0604011D0AAACAC 0604011G0BJACBR 0604011L0AABABA 0604011L0BWAABJ 
0604011D0AAAEAE 0604011G0BKAABM 0604011L0AABDBD 0604011L0BXAAAK 
0604011D0AAALAL 0604011G0BKABBQ 0604011L0AABEBE 0604011L0BYAAAF 
0604011D0AAARAR 0604011G0BKACBP 0604011L0AABFBF 0604011L0BZAABK 
0604011D0AAAWAW 0604011G0BLAABM 0604011L0AABGBG 0604011L0CBAAA0 
0604011D0AABDBD 0604011G0BLABBP 0604011L0AABKBK 0604011M0BBABAB 
0604011D0AABEBE 0604011G0BMAABD 0604011L0BBAABB 0604011N0BBAAAA 
0604011G0AAAAAA 0604011G0BMABAI 0604011L0BBABBC 0604011P0AAABAB 
0604011G0AAABAB 0604011G0BMACBE 0604011L0BCAAAB 0604011P0AAACAC 
0604011G0AAACAC 0604011G0BMADBG 0604011L0BCABAC 0604011P0AAADAD 
0604011G0AAAIAI 0604011G0BNAABA 0604011L0BEAAAF 0604011P0AAAFAF 
0604011G0AAAUAU 0604011G0BNABBL 0604011L0BEABAZ 0604011P0BBAAAB 
0604011G0AABABA 0604011G0BNACBN 0604011L0BEACAK 0604011P0BBABAC 
0604011G0AABDBD 0604011G0BNAEBL 0604011L0BFAAAG 0604011P0BBACAD 
0604011G0AABIBI 0604011G0BNAFBR 0604011L0BGAAAH 0604011P0BBAGAF 
0604011G0AABJBJ 0604011G0BPAABI 0604011L0BGABAI 0604011Q0AAACAC 
0604011G0AABLBL 0604011G0BPABBJ 0604011L0BHAAAJ 0604011Q0AAADAD 
0604011G0AABNBN 0604011G0BRAAAI 0604011L0BHABAX 0604011Q0AAAEAE 
0604011G0AABQBQ 0604011G0BSAABS 0604011L0BHACAY 0604011Q0AAAHAH 
0604011G0AABRBR 0604011G0BUAABR 0604011L0BIAAAK 0604011Q0BBACAC 
0604011G0AABSBS 0604011G0BUABBN 0604011L0BJAAAL 0604011Q0BBADAD 
0604011G0BCAABL 0604011G0BUACBA 0604011L0BKAAAM 0604011Q0BCACAG 
0604011G0BCABBA 0604011G0BUADBH 0604011L0BKABAN 0604011Q0BCADAE 
0604011G0BCACBN 0604011G0BUAEBL 0604011L0BKACAP 0604011Q0BCAEAH 
0604011G0BCADBA 0604011G0BVAAAI 0604011L0BKADBD 0604011R0AAAAAA 
0604011G0BCAEBL 0604011H0BBAAAA 0604011L0BKAEBL 0604011R0BBAAAA 
0604011G0BCAFBN 0604011J0BBAAAA 0604011L0BLAAAQ 0604011Y0AAAAAA 
0604011G0BCAGBR 0604011J0BBABAB 0604011L0BLABAU 0604011Y0AAABAB 
0604011G0BEAAAI 0604011K0AAAAAA 0604011L0BMAAAR 0604011Y0BBAAAA 
0604011G0BEABBD 0604011K0AAABAB 0604011L0BPAAAT 
 
0604011G0BFAABL 0604011K0BBAAAA 0604011L0BPABAW 
 
0604011G0BFABBA 0604011K0BBABAB 0604011L0BPACAK 
 
0604011G0BFACBR 0604011K0BCAAAA 0604011L0BRAABA 
 
0604011G0BFADBN 0604011K0BCABAB 0604011L0BSAAAI 
 
0604011G0BHAABG 0604011K0BEAAAA 0604011L0BTAABE 
 




Supplementary Table 2. Average prescribing rates (and 95% confidence intervals [CIs]) of oestrogen-
containing hormone replacement therapy per 1000 registered females over the age of 40 years, for 
practices in each deprivation decile, as defined by the Index of Multiple Deprivation (IMD) score. 
Figures are given for 2018 in England. 
 
      
IMD Decile Items per 1000  (95% CI) 
1 228 (222, 234) 
2 219 (212, 225) 
3 207 (201, 213) 
4 201 (195, 207) 
5 182 (176, 187) 
6 175 (169, 181) 
7 165 (159, 170) 
8 158 (152, 164) 
9 152 (147, 158) 














Supplementary Table 3. Summary of unadjusted and adjusted regression analyses for the rate of 
prescribing of all oestrogen-containing hormone replacement therapy. The results for all variables 
included in the multivariable model are given. Quintile 1 – the lowest quintile – is the reference for all 
variables.  (IRR = incidence rate ratio; aIRR = adjusted incidence rate ratio; CI = confidence interval; 
HRT = hormone replacement therapy; IMD = Index of Multiple Deprivation). 
                    
    Unadjusted   Adjusted 
        IRR (95% CI)     aIRR (95% CI) 
Index of Multiple 
Deprivation score Quintile 1 Reference 1 
   1  
  2  0.91 (0.89 - 0.94)   0.97 (0.94 - 1.00) 
  3  0.80 (0.77 - 0.82)   0.89 (0.85 - 0.92) 
  4  0.72 (0.70 - 0.74)   0.82 (0.79 - 0.86) 
    5   0.71 (0.68 - 0.73)     0.82 (0.77 - 0.86) 
Practice list size of 
female aged 40 
years and above 
Quintile 1 Reference 1    1  
 2  0.98 (0.94 - 1.01)   0.94 (0.91 - 0.97) 
  3  1.01 (0.97 - 1.05)   0.93 (0.90 - 0.96) 
  4  1.03 (1.00 - 1.07)   0.92 (0.88 - 0.95) 




Quintile 1 Reference 1    1  
  2  0.92 (0.89 - 0.95)   1.02 (0.99 - 1.06) 
  3  0.82 (0.79 - 0.85)   1.01 (0.97 - 1.05) 
  4  0.76 (0.73 - 0.78)   1.02 (0.98 - 1.07) 




Quintile 1 Reference 1    1  
  2  0.90 (0.87 - 0.93)   0.96 (0.93 - 0.99) 
  3  0.89 (0.86 - 0.92)   0.97 (0.94 - 1.00) 
  4  0.86 (0.83 - 0.89)   0.98 (0.95 - 1.02) 




Quintile 1 Reference 1    1  
 
 2  0.99 (0.96 - 1.03)   0.96 (0.93 - 1.00) 
 
 3  1.05 (1.02 - 1.09)   0.99 (0.95 - 1.04) 
 
 4  1.05 (1.01 - 1.08)   1.00 (0.95 - 1.05) 





Quintile 1 Reference 1    1  
 
 2  0.9 (0.87 - 0.93)   0.85 (0.82 - 0.88) 
 
 3  0.85 (0.82 - 0.87)   0.80 (0.78 - 0.83) 
 
 4  0.79 (0.76 - 0.81)   0.76 (0.73 - 0.79) 





Quintile 1 Reference 1    1  
 2  1.09 (1.06 - 1.13)   1.05 (1.01 - 1.10) 
 
 3  1.11 (1.07 - 1.15)   1.07 (1.02 - 1.12) 
 
 4  1.12 (1.08 - 1.15)   1.11 (1.05 - 1.17) 
    5   1.05 (1.02 - 1.09)     1.08 (1.02 - 1.15) 
Practice 
prevalence of 
stroke or transient 
ischaemic attack 
Quintile 1 Reference 1    1  
 2  1.16 (1.12 - 1.20)   1.15 (1.11 - 1.20) 
 3  1.18 (1.14 - 1.22)   1.17 (1.11 - 1.22) 
 
 4  1.19 (1.15 - 1.24)   1.19 (1.13 - 1.25) 







Supplementary Table 4. Summary of unadjusted and adjusted regression analyses for the rate of 
prescribing of oral oestrogen-containing hormone replacement therapy. The results for all variables 
included in the multivariable model are given. Quintile 1 – the lowest quintile – is the reference for all 
variables.  (IRR = incidence rate ratio; aIRR = adjusted incidence rate ratio; CI = confidence interval; 
HRT = hormone replacement therapy; IMD = Index of Multiple Deprivation). 
                    
    Unadjusted   Adjusted 
        IRR (95% CI)     aIRR (95% CI) 
Index of Multiple 
Deprivation score Quintile 1 Reference 1 
   1  
  2  0.99 (0.96 - 1.02)   0.99 (0.96 - 1.03) 
  3  0.88 (0.85 - 0.91)   0.89 (0.85 - 0.92) 
  4  0.85 (0.82 - 0.88)   0.85 (0.81 - 0.89) 
    5   0.83 (0.81 - 0.86)   0.81 (0.76 - 0.86) 
Practice list size of 
female aged 40 
years and above 
Quintile 1 Reference 1    1  
 2  0.86 (0.83 - 0.89)   0.84 (0.81 - 0.87) 
  3  0.86 (0.84 - 0.90)   0.82 (0.79 - 0.85) 
  4  0.88 (0.85 - 0.91)   0.82 (0.79 - 0.85) 




Quintile 1 Reference 1    1  
  2  0.99 (0.96 - 1.02)   1.06 (1.02 - 1.10) 
  3  0.92 (0.89 - 0.95)   1.08 (1.03 - 1.12) 
  4  0.88 (0.85 - 0.91)   1.10 (1.05 - 1.15) 




Quintile 1 Reference 1    1  
  2  0.97 (0.93 - 1.00)   0.99 (0.96 - 1.03) 
  3  0.98 (0.95 - 1.02)   1.02 (0.99 - 1.06) 
  4  0.96 (0.92 - 0.99)   1.01 (0.98 - 1.05) 




Quintile 1 Reference 1    1  
 
 2  1.03 (0.99 - 1.07)   0.99 (0.95 - 1.03) 
 
 3  1.08 (1.04- 1.12)   1.01 (0.96 - 1.05) 
 
 4  1.07 (1.03 -1.11)   1.01 (0.96 - 1.06) 





Quintile 1 Reference 1    1  
 
 2  0.97 (0.94 - 1.00)   0.90 (0.87 - 0.93) 
 
 3  0.94 (0.91 - 0.97)   0.87 (0.84 - 0.90) 
 
 4  0.90 (0.87 - 0.93)   0.83 (0.80 - 0.87) 





Quintile 1 Reference 1    1  
 2  1.11 (1.07 - 1.15)   1.06 (1.01 - 1.11) 
 
 3  1.12 (1.08 - 1.16)   1.09 (1.03 - 1.16) 
 
 4  1.13 (1.09 - 1.17)   1.13 (1.06 - 1.20) 
    5   1.06 (1.02 - 1.09)   1.09 (1.02 - 1.17) 
Practice 
prevalence of 
stroke or transient 
ischaemic attack 
Quintile 1 Reference 1    1  
 2  1.15 (1.10 - 1.19)   1.13 (1.09 - 1.19) 
 3  1.16 (1.11 - 1.20)   1.14 (1.08 - 1.21) 
 
 4  1.13 (1.09 - 1.17)   1.12 (1.06 - 1.19) 




Supplementary Table 5. Summary of unadjusted and adjusted regression analyses for the rate of 
prescribing of transdermal oestrogen-containing hormone replacement therapy. The results for all 
variables included in the multivariable model are given. Quintile 1 – the lowest quintile – is the 
reference for all variables.  (IRR = incidence rate ratio; aIRR = adjusted incidence rate ratio; CI = 
confidence interval; HRT = hormone replacement therapy; IMD = Index of Multiple Deprivation). 
                    
    Unadjusted   Adjusted 
        IRR (95% CI)     aIRR (95% CI) 
Index of Multiple 
Deprivation score Quintile 1 Reference 1 
   1  
  2  0.86 (0.82 - 0.90)   0.97 (0.93 - 1.02) 
  3  0.76 (0.72 - 0.79)   0.95 (0.90 - 1.01) 
  4  0.70 (0.67 - 0.73)   0.95 (0.89 - 1.01) 
    5   0.68 (0.65 - 0.71)   0.97 (0.90 - 1.04) 
Practice list size of 
female aged 40 
years and above 
Quintile 1 Reference 1    1  
 2  0.84 (0.80 - 0.88)   0.84 (0.81 - 0.88) 
  3  0.82 (0.78 - 0.86)   0.81 (0.78 - 0.85) 
  4  0.78 (0.74 - 0.81)   0.76 (0.72 - 0.79) 




Quintile 1 Reference 1    1  
  2  0.86 (0.82 - 0.90)   0.94 (0.89 - 0.98) 
  3  0.74 (0.71 - 0.78)   0.86 (0.82 - 0.91) 
  4  0.66 (0.63 - 0.70)   0.80 (0.76 - 0.85) 




Quintile 1 Reference 1    1  
  2  0.83 (0.79 - 0.87)   0.95 (0.91 - 0.99) 
  3  0.76 (0.73 - 0.80)   0.92 (0.88 - 0.97) 
  4  0.74 (0.71 - 0.77)   0.94 (0.89 - 0.99) 




Quintile 1 Reference 1    1  
 
 2  0.86 (0.82 - 0.90)   0.98 (0.94 - 1.03) 
 
 3  0.87 (0.83 - 0.91)   1.02 (0.97 - 1.08) 
 
 4  0.85 (0.82 - 0.89)   1.03 (0.97 - 1.10) 





Quintile 1 Reference 1    1  
 
 2  0.81 (0.77 - 0.84)   0.85 (0.81 - 0.89) 
 
 3  0.71 (0.68 - 0.75)   0.79 (0.75 - 0.84) 
 
 4  0.67 (0.64 - 0.70)   0.77 (0.73 - 0.82) 





Quintile 1 Reference 1    1  
 2  0.96 (0.91 - 1.00)   1.00 (0.95 - 1.06) 
 
 3  0.88 (0.84 - 0.92)   0.95 (0.88 - 1.02) 
 
 4  0.87 (0.83 - 0.91)   0.96 (0.89 - 1.03) 
    5   0.80 (0.77 - 0.84)   0.88 (0.81 - 0.96) 
Practice 
prevalence of 
stroke or transient 
ischaemic attack 
Quintile 1 Reference 1    1  
 2  0.98 (0.94 - 1.03)   1.08 (1.03 - 1.14) 
 3  0.89 (0.85 - 0.93)   1.05 (0.99 - 1.12) 
 
 4  0.92 (0.88 - 0.97)   1.11 (1.03 - 1.19) 
    5   0.90 (0.86 - 0.94)   1.08 (1.00 - 1.17) 
 
 
